Jefferies Financial Group Inc. Acquires Shares of 1,580,625 Eledon Pharmaceuticals, Inc. $ELDN

Jefferies Financial Group Inc. acquired a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,580,625 shares of the company’s stock, valued at approximately $2,387,000. Jefferies Financial Group Inc. owned about 2.64% of Eledon Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of ELDN. Zimmer Partners LP raised its stake in shares of Eledon Pharmaceuticals by 86.1% during the 3rd quarter. Zimmer Partners LP now owns 1,825,000 shares of the company’s stock valued at $4,727,000 after buying an additional 844,318 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Eledon Pharmaceuticals by 107.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,383,940 shares of the company’s stock valued at $3,751,000 after buying an additional 717,223 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at about $947,000. First Light Asset Management LLC raised its stake in shares of Eledon Pharmaceuticals by 11.7% during the 2nd quarter. First Light Asset Management LLC now owns 2,600,498 shares of the company’s stock valued at $7,047,000 after buying an additional 271,730 shares during the last quarter. Finally, CM Management LLC raised its stake in shares of Eledon Pharmaceuticals by 60.0% during the 3rd quarter. CM Management LLC now owns 600,000 shares of the company’s stock valued at $1,554,000 after buying an additional 225,000 shares during the last quarter. Hedge funds and other institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Price Performance

Shares of Eledon Pharmaceuticals stock opened at $3.89 on Wednesday. Eledon Pharmaceuticals, Inc. has a twelve month low of $1.35 and a twelve month high of $4.60. The business has a 50-day moving average price of $3.42 and a 200 day moving average price of $2.49. The firm has a market cap of $300.27 million, a PE ratio of -5.05 and a beta of 0.94.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.11). On average, sell-side analysts expect that Eledon Pharmaceuticals, Inc. will post -0.91 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen lowered Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.67.

Eledon Pharmaceuticals Profile

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.